By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches
AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches
Health

AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches

GlobeNews Wire
Last updated: 23/07/2025 7:57 PM
GlobeNews Wire
Published: 23/07/2025
Share
SHARE

BERWYN, Pa., July 23, 2025 (GLOBE NEWSWIRE) — AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces service and infrastructure enhancements designed to help specialty and rare disease drug manufacturers respond to accelerating market disruption across the pharmaceutical landscape. From sudden formulary exclusions and loss of preferred status to the growing impact of biosimilars, generics and aggressive cost-containment measures by payers, manufacturers rely upon a strategic, flexible distribution partnership with AscellaHealth.

“This is a wake-up call for biopharma manufacturers,” says Bill Oldham, chairman and president of AscellaHealth. “When preferred drug status can be lost overnight, it’s essential to have a pharmacy-first HUB partner that scales with you, minimizes disruption and delivers what’s best for patients and the product.”

As the recent shift in UnitedHealthcare’s formulary status for Stelara® illustrates, biopharma companies must act quickly to prepare for sudden market access changes. With these pressures intensifying, the need for AscellaHealth’s high-touch, patient-first model is greater than ever. Combined with leading technology and data capabilities, AscellaHealth positions manufacturers to respond with agility, protect product access and ensure patient continuity of care.

“AscellaHealth’s integrated HUB model ensures manufacturers maintain full control over their product, patients, and critical program data—regardless of payer shifts, employer transitions or market disruptions,” continues Oldham. “Patients benefit from a consistent, reliable support system, while manufacturers can trust in a distribution partner that scales seamlessly and prioritizes uninterrupted access and continuity of care.”

Enhanced capabilities, enabling manufacturers to mitigate risk and maintain product value throughout the drug lifecycle, include:

1. Optimized Plan Design & Formulary Management

AscellaHealth leverages deep expertise in formulary dynamics and cost-containment strategies to help manufacturers maintain access while navigating payer and PBM shifts.

2. Patient Engagement Technology

A new mobile platform enables HIPAA-compliant messaging, document sharing and video support—ensuring personalized, multi-channel engagement that improves adherence and satisfaction.

3. Real-Time Data & Analytics

Combining the power of Microsoft’s ecosystem of business intelligence through Power BI, Power Platform, CoPilot for AI and CRM, in conjunction with proprietary analytics tools, AscellaHealth offers actionable insights into program health. With real time business analytics, integrated reporting, and alert monitoring, it allows internal stakeholders and manufacturer partners to drive smarter decisions faster.

4. Alternative Distribution & Market Access Strategy

With experience across exclusive, limited and open distribution models, AscellaHealth helps manufacturers choose the right channel strategy, optimize site-of-care and educate providers to support adoption.

These timely advancements are supported by infrastructure investments in both technology and facilities. A phased upgrade to WellSky’s cutting edge healthcare software continues to enhance care coordination, optimize clinical and financial workflows and improve patient engagement through tailored, integrated solutions. The ongoing expansion of patient support facility, Optime Care East, increases AscellaHealth’s ability to manage high-acuity patient populations and deliver enhanced care management solutions globally.

About AscellaHealth

AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

About Optime Care

Optime Care, Inc., AscellaHealth’s Specialty Pharmacy, is a nationally recognized specialty pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize therapeutic opportunities for the treatment of orphan and rare disorders. The executive team has partnered in the launch and management of over 40 orphan products and programs while consistently implementing the best brand services for the community. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. Visit: https://www.optimecare.com/

*Optime Care is wholly owned by Innovative Specialty Solutions, LLC, an affiliate of AscellaHealth, LLC.

This press release was published by a CLEAR® Verified individual.



Ski Jumping: yellow and red card sanctions among changes to be introduced for equipmentrelated infractions in 2025/26
Sun Life Survey Reveals Financial Security Tops Legacy Planning Priorities But Families Worry Wealth Won’t Last Beyond Next Generation
The Moonhouse: The First Ever House on the Moon – A Swedish Red Cottage Set to Land June 5
Visit Las Vegas and ComplexCon Unveil Custom Daniel Arsham Sculpture Inspired by the Iconic Welcome to Fabulous Las Vegas Sign
Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology
TAGGED:acrossandascellahealthbiosimilarbranddrugenhancementsgenericinfrastructurelaunchesmanufacturersmarketnewsprotectservicesharespecialtysupport
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Andor Health’s Agentic AI Platform, ThinkAndor, Receives Frost & Sullivan’s 2025 North American Transformational Innovation Leadership Recognition for Excellence in Acute Care Virtual Health
News

Andor Health’s Agentic AI Platform, ThinkAndor, Receives Frost & Sullivan’s 2025 North American Transformational Innovation Leadership Recognition for Excellence in Acute Care Virtual Health

06/11/2025
TACC Limited and CRRI Collaborate to Revolutionize Indian Infrastructure with Graphene-Enhanced Pavements
Eightco Holdings Inc. (ORBS) Announces 16.9 Million Verified World Humans, Adding 1.9 Million Since Launching Worldcoin Treasury Just 3 Weeks Ago
Hyundai Motor Group and Incheon International Airport to Deliver NextLevel Convenience with AIPowered EV Charging Robots
C3.AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against C3.ai, Inc. – AI
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?